Annual Research Support Sample Clauses

Annual Research Support. Xxxxxxxx will provide funding to Senomyx for [***] for the first three (3) years, such rate to be increased for inflation using the Aon Consulting/Xxxxxxx Division report for industry compensation. Research support payments will be made by Xxxxxxxx according to the following schedule: [***] [***] [***] [***] [***] [***] [***] These payments are inclusive of overhead, labor, and supplies. These payments do not include (i) Campbell's costs associated with providing support for the collaboration; (ii) the costs of any unanticipated materials as requested and agreed to by the parties; or (iii) the costs of high throughput screening over [***]. Additional funding, if any, will be proposed to the Steering Committee and agreed to in writing by the parties.
Sample 1Sample 2
AutoNDA by SimpleDocs
Annual Research Support. Each year during the Collaborative Period, Senomyx shall pay Aurora for [***] FTEs at an annual rate of [***] per FTE. These payments shall be made in advance on an equal quarterly basis. The first payment shall be made within ten (10) business days following the Effective Date. These payments are inclusive of overhead, labor, and supplies; provided, however, that in any given year, a portion of these payments may be allocated to cover the cost of high throughput screening of Senomyx Compounds by Aurora [***] with a commensurate reduction in the allocation of payments for FTEs. These payments shall not cover the cost associated with providing the Compound Supply to Aurora or other unanticipated materials, as agreed to by the parties in advance in writing, or the costs of high throughput screening for over [***]. Additional funding, if any, shall be proposed by the Steering Committee and agreed to by the parties in advance in writing.
Sample 1Sample 2
Annual Research Support. Each year during the Collaborative Period, Nestlé will pay Senomyx [***] per year for the Collaborative Programs, [***] for the [***] Program and [***] for the [***] Program. The payments will be made in advance and on an equal quarterly basis. The first payment will be made within [***] following the Effective Date. These payments are inclusive of overhead, labor, and supplies. These payments do not include (i) Nestlé's costs associated with providing support for the collaboration; or (ii) the costs of any unanticipated materials as requested and agreed to by the parties. Additional funding, if any, will be proposed to the Steering Committees and agreed to in writing by the parties.
Sample 1
Annual Research Support. Each year during the Collaborative Period Kraft will pay Senomyx $1,375,000 (which represents the full time equivalent of [***] Senomyx scientists at an annual rate of [***] per scientist based on [***] per year), such rate to be increased for inflation using the Aon Consulting/Xxxxxxx Division report for industry compensation each year; provided, however, that if in any calendar year the annual amount to be paid to Senomyx exceeds $1,375,000, Kraft may elect, in its sole discretion, to decrease the number of full time equivalents such that the annual amount to be paid to Senomyx remains at $1,375,000. These payments will be made in advance and, at a minimum, on an equal quarterly basis. The first payment will be made within [***] following the Effective Date. These payments are inclusive of overhead, labor, and supplies. These payments do not include (i) Kraft's costs associated with providing [***] Tastants and [***] Tastants; (ii) the costs of any unanticipated materials as requested and agreed to by the parties; or (iii) the costs of high throughput screening over [***]. Additional funding, if any, will be proposed to the Steering Committee and agreed to in writing by the parties.
Sample 1
Annual Research Support. Each year during the Collaborative Period Kraft will pay Senomyx $1,375,000 (which represents the full time equivalent of [...***...] Senomyx scientists at an annual rate of [...***...] per scientist based on a minimum of [...***...] hours per year), such rate to be increased for inflation using the Aon Consulting/Xxxxxxx Division report for industry compensation each year; provided, however, that if in any calendar year the annual amount to be paid to Senomyx exceeds [...***...], Kraft may elect, in its sole discretion, to decrease the number of full time equivalents such that the annual amount to be paid to Senomyx remains at [...***...]. These payments will be made in advance and, at a minimum, on an equal quarterly basis. The first payment will be made within [...***...] following the Effective Date. These payments are inclusive of overhead, labor, and supplies. These payments do not include (i) Kraft's costs associated with providing [...***...]
Sample 1
Annual Research Support. Each year during the Collaborative Period, Senomyx shall pay Aurora for [...***...] FTEs at an annual rate of [...***...]
Sample 1
Annual Research Support. 9.1.1 Funding Amount Each year during the Collaborative R&D Period, KO will pay SENOMYX $2,000,000 for the services provided in accordance with the Agreement. Upon achievement of [***], KO will cease making payments for research and development and instead make annual payments of $2,000,000 (prorated for any amount previously paid for research and development for such year) in order to adapt and continue to develop the then existing capabilities/intellectual property for further enhancement of commercial opportunities during the Collaborative R&D Period.
Sample 1
AutoNDA by SimpleDocs
Annual Research Support. IL agrees to provide the research support set forth in Attachment 2 for the following year, beginning on the Effective Date of this Agreement. On an annual basis the Research Steering Committee shall agree on the amount of such research support and the allocation of such support to Sheffield Investigators. Attachment 2 shall be modified yearly to reflect each years' annual research support. The research support provided shall be in support of the Research Program and be incorporated as part of the Annual Research Plan developed by the Research Steering Committee.
Sample 1
Annual Research Support 
Sample 1

Related to Annual Research Support

  • Research Program The term “Research Program” shall mean the research program to be undertaken by TSRI under the direction and control of the Principal Investigator as expressly set forth on Exhibit A hereto.

  • Research Neither the Investor nor any Affiliate of the Investor shall have, in the prior thirty (30) days, published or distributed any research report (as such term is defined in Rule 500 of Regulation AC) concerning the Company.

  • Research Program Term The Research Program shall be conducted during the period of five years commencing as of the Agreement Date ("Research Program Term"). Upon not later than seventy-five (75) days' prior written notice JT may, in its sole judgment, terminate the Research Program at the end of the third (3/rd/) year and fourth (4/th/) year of the Research Program. The RMC may terminate the Research Program any time during the Research Program Term if it unanimously determines the Research Program is no longer scientifically useful or that all potential Products would not be commercially viable. In case of such an early termination by JT or the RMC, JT shall be exempt from any payment(s) under Section 10(a) that would have become due and payable after the effective date of such early termination. Following any termination of the Research Program (i) that occurs simultaneously with the termination of this Agreement in accordance with Section 13 (i.e., no compound or Lead Compound has been designated previously a Collaboration Lead Compound in accordance with Section 3(b) and no Independent Lead Compound is being developed in accordance with Section 3(m)) or (ii) that is followed at some future date by the termination by JT of Development or co-promotion of any Collaboration Lead Compound and/or Product pursuant to Sections 3(l) or 5(c), respectively, or development of an Independent Lead Compound in accordance with Section 3(m) (A) any licenses granted by Tularik to JT will terminate, (B) JT will grant to Tularik an exclusive, sublicensable, worldwide license, to make, use and sell compounds, Collaboration Lead Compounds or Products under JT's interest in Program Patents and Program Know-How and (C) under the terms and conditions to be separately agreed, JT will also grant to Tularik a nonexclusive, sublicensable, worldwide license under any JT Patent Rights and Know-How to the extent necessary to practice the license granted under the Program Patents and Program Know-How in (B) (including, with respect to compounds, a limited number of JT's library compounds approved by JT); provided, however, that in the event the Research Program terminates but the Agreement has not terminated with respect to designated Collaboration Lead Compounds, Independent Lead Compounds and/or Products as provided in Section 2(g)(ii), Sections 2(g)(A), (B) and (C) shall apply only to those compounds, Collaboration Lead Compounds, Independent Lead Compounds and Products for which Development or co-promotion shall have been terminated and/or to those compounds or Lead Compounds that have not been designated previously a Collaboration Lead Compound in accordance with Section 3(b) or an Independent Lead Compound in accordance with Section 3(m); provided further that in the event that JT elects to pursue a Discontinued Compound or a Non-Proposed Compound on or before the first anniversary of the expiration or termination of the Research Program Term pursuant to Section 3(b)(iii) or 3(b)(iv), respectively, Sections 2(g)(A), (B) and (C) shall not apply to such Discontinued Compound or Non-Proposed Compound until such time as JT shall have terminated the Development or co-promotion of such Discontinued Compound or Non- Proposed Compound. Tularik will then be free to pursue clinical development and registration of such compounds, Lead Compounds and/or Products without obligation to JT except as provided in Section 4(f) or Section 5(c), as appropriate.

  • Conduct of Research Program Each Party:

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Compliance Support Services Provide compliance policies and procedures related to services provided by BNY Mellon and, if mutually agreed, certain of the BNY Mellon Affiliates; summary procedures thereof; and periodic certification letters. · Such Compliance Support Services are administrative in nature and do not constitute, nor shall they be construed as constituting, legal advice or the provision of legal services for or on behalf of a Fund or any other person, and such services are subject to review and approval by the applicable Fund and by the Fund’s legal counsel. · Provide access to Fund records so as to permit the Fund or TRP to test the performance of BNY Mellon in providing the services under this Agreement. · Such Compliance Support Services performed by BNY Mellon under this Agreement shall be at the request and direction of the Fund and/or its chief compliance officer (the “Fund’s CCO”), as applicable. BNY Mellon disclaims liability to the Fund, and the Fund is solely responsible, for the selection, qualifications and performance of the Fund’s CCO and the adequacy and effectiveness of the Fund’s compliance program.

  • Investment Advice and Research Services If and to the extent requested by the Sub-Advisor, the U.K. Sub-Advisor shall provide investment advice and research services to the Sub-Advisor with respect to all or a portion of the investments of each Portfolio. In connection with providing such investment advice and research services, the U.K. Sub-Advisor shall furnish to the Sub-Advisor on behalf of each Portfolio such factual information, research reports and investment recommendations as the Advisor may reasonably require. Such information may include written and oral reports and analyses.

  • Research Independence The Company acknowledges that each Underwriter’s research analysts and research departments, if any, are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that such Underwriter’s research analysts may hold and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of its investment bankers. The Company hereby waives and releases, to the fullest extent permitted by law, any claims that the Company may have against such Underwriter with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research departments may be different from or inconsistent with the views or advice communicated to the Company by such Underwriter’s investment banking divisions. The Company acknowledges that the Representative is a full service securities firm and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short position in debt or equity securities of the Company.

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Collaboration Each Party shall provide to the enforcing Party reasonable assistance in such enforcement, at such enforcing Party’s request and expense, including to be named in such action if required by Applicable Laws to pursue such action. The enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts, shall reasonably consider the other Party’s comments on any such efforts, including determination of litigation strategy and filing of material papers to the competent court. The non-enforcing Party shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the enforcing Party.

Time is Money Join Law Insider Premium to draft better contracts faster.